On the occasion of World Tuberculosis Day, Jennifer Herrmann, scientist in the department Microbial Natural Products at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), talks about the epidemiology...
After exposure to a virus through infection or vaccination, the body activates a number of cells and mechanisms that can provide targeted defense against the pathogen. For the global containment of the SARS-CoV-2...
In May 2020, the international consortium iCAIR® started a research project aimed at developing therapeutics against SARS-CoV-2. The Helmholtz Centre for Infection Research (HZI), which joined forces with the...
Every year, about 10 million people become infected with tuberculosis and 1.4 million die from it. This makes tuberculosis not only one of the most widespread infectious diseases, but also the deadliest. Similar to...
The bacterium Pseudomonas aeruginosa is among the most common causes of pneumonia and poses a major challenge to hospitals worldwide. The treatment of infections with Pseudomonas aeruginosa is usually challenging...
An international research team of the Technische Universität Braunschweig and the Helmholtz Centre for Infection Research (HZI), led by the Department of Biotechnology of the TU Braunschweig, has reported on the...
Therapeutically modified white blood cells hold great potential in the treatment of multiple myeloma, a malignant cancer of the bone marrow. However, they can lead to serious resistance in treated patients. In close...
The CoVerage tool analyses the lineage dynamics of SARS-CoV-2 strains, i.e. determines how successfully which virus strain spreads. The web resource uses input from the Gisaid genome database. Gisaid is an international...
The NoCovid group’s scientists, including HZI researchers Prof Melanie Brinkmann and Prof Michael Meyer-Hermann, have called for extensive testing, faster contact tracing, and a rapid rollout of vaccinations in Germany,...
